Document is current

Article History

Received: 7 August 2025

Revised: 8 October 2025

Accepted: 21 October 2025

First Online: 23 December 2025

Compliance with ethical standards

:

: Daiichi Sankyo Co., Ltd., supported all authors with medical writing and article processing charges; all authors (except for M Ohishi, T Shimosawa, K Shiosakai, T Furugori, and T Taguchi) with research funding; and M Ohishi, K Kario, T Katsuya, and T Shimosawa with advisory fees. M Ohishi received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Kowa Co., Ltd. K Kario received research grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Pharmaceuticals Japan G.K.; and is an advisory board member of Daiichi Sankyo Co., Ltd. and Novartis Pharma K.K. T Katsuya received honoraria from Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., AstraZeneca K.K., CureApp, Inc., Taisho Pharmaceutical Co., Ltd., and Moderna Japan Co., Ltd.; and payment for expert testimony from CureApp, Inc. and Novartis Pharma K.K. T Shimosawa received research funding from Takenaka Co., Ltd., FUJIFILM Corp., Nippon Boehringer Ingelheim Co., Ltd., Teijin Pharma Ltd., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.; consultant fees from Sekisui Medical Co., Ltd. and EP Mediate Co., Ltd.; honoraria from Novartis Pharma K.K., Taisho Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AEON Co., Ltd., FUJIFILM Corp., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Elsevier Japan K.K., Abbott Japan LLC., and Eiken Chemical Co., Ltd.; is a board member of Otsuka Medical Devices Co., Ltd. and Daiichi Sankyo Co., Ltd.; and is the chair of CVEM2023 and deputy director and educational seminars chair of the Japanese Society of Medical Use of Functional Foods, and the steering committee of the Angiotensin Gordon Research Conference. K Shiosakai, T Furugori, and T Taguchi are employees of Daiichi Sankyo Co., Ltd.

: The study design and primary analysis of the EXCITE-HT study have been previously published (Kario K, et al. J Clin Hypertens (Greenwich) 2023;25:861–7, and Kario K, et al. Hypertens Res 2024;47:2435–46).